Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 1/20 | 0.47 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 2/20 | 0.47 |
| ▸ | PPARA | Q07869 | 5/20 | 0.42 |
| ▸ | PPARG | P37231 | 5/20 | 0.42 |
| ▸ | MTOR | P42345 | 1/20 | 0.41 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.41 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.41 |
| ▸ | ACP3 | P15309 | 2/20 | 0.41 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.40 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.39 |
| ▸ | FPR2 | P25090 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5750437 | 0.87 | PPARG (0.51) | SLC1A1PPARAPPARGMDM2ACP3 | |
| SCHEMBL5751624 | 0.84 | PPARG (0.44) | PPARAPPARGL3MBTL1CNR2 | |
| SCHEMBL5749682 | 0.84 | PPARG (0.44) | PPARAPPARGL3MBTL1CNR2 | |
| SCHEMBL5751870 | 0.84 | AKR1C3 (0.47) | PPARAPPARGL3MBTL1CNR2 | |
| SCHEMBL5753401 | 0.81 | SLC7A5 (0.45) | OPRM1OPRL1MTORFFAR2ACP3 | |
| SCHEMBL5752665 | 0.80 | PDE2A (0.46) | SLC1A1PPARAPPARGL3MBTL1 | |
| SCHEMBL5750572 | 0.79 | PPARA (0.43) | PPARAPPARGFFAR2L3MBTL1FPR2 | |
| SCHEMBL5753842 | 0.78 | PPARG (0.57) | PPARAPPARGFFAR2L3MBTL1CNR2 | |
| SCHEMBL5751805 | 0.78 | SLC1A1 (0.47) | OPRM1SLC1A1PPARAPPARGMDM2 | |
| SCHEMBL5752822 | 0.77 | PPARG (0.47) | SLC1A1PPARAPPARGL3MBTL1PDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | OPRM1 2976/4885OPRL1 1125/4885SLC1A1 343/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.